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Introduction: The patient’s perspective is becoming increasingly important in clinical and policy decisions. In this
study, we aimed to evaluate the preferences of patients with, or at risk of, osteoporosis for medication attributes,
and to establish how patients trade between these attributes.
Methods: A discrete choice experiment survey was designed and patients were asked to choose between two
hypothetical unlabelled drug treatments (and an opt-out option) that vary in five attributes: efficacy in reducing the
risk of fracture, type of potential common side-effects, mode and frequency of administration and out-of-pocket
costs. An efficient experimental design was used to construct the treatment option choice sets and a mixed logit
panel data model was used to estimate patients’ preferences and trade-offs between attributes.
Results: A total of 257 patients with, or at risk of, osteoporosis completed the experiment. As expected, patients
preferred treatment with higher effectiveness and lower cost. They also preferred either an oral monthly tablet or
6-month subcutaneous injection above weekly oral tablets, 3-month subcutaneous, 3-month intravenous or yearly
intravenous injections. Patients disliked being at risk of gastro-intestinal disorders more than being at risk of skin
reactions and flu-like symptoms. There was significant variation in preferences across the sample for all attributes
except subcutaneous injection.
Conclusions: This study revealed that osteoporotic patients preferred 6-month subcutaneous injection and
oral monthly tablet, and disliked gastro-intestinal disorders. Moreover, patients were willing to pay a personal
contribution or to trade treatment efficacy for better levels of other attributes. Preferences for treatment attributes
varied across patients and this highlights the importance of clinical decision-making taking individual preferences
into account to improve osteoporosis care.Introduction
The patient’s perspective is becoming increasingly im-
portant in clinical and policy decisions. Information
about what patients need and prefer, and how they value
various aspects of a health intervention can be useful
when designing and evaluating healthcare programs [1].
A better understanding of patients’ preferences for treat-
ment can help health professionals to improve disease
management. When differences in efficacy or safety do
not determine the choice of a specific treatment, pa-
tient’s satisfaction with therapy is important [2].* Correspondence: m.hiligsmann@maastrichtuniversity.nl
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distribution, and reproduction in any mediumAddressing patients’ concerns with treatment and in-
volving them in clinical decision-making may also im-
prove adherence [1]. Patients increasingly want to be
informed by their doctors, and to be active in clinical
decision-making [3,4]. In recent years, discrete choice
experiments (DCEs) have been increasingly used to elicit
patients’ preferences for healthcare [5,6]. DCEs can quan-
tify the relative importance of the various attributes that
characterize a treatment and allow the trade-offs that re-
spondents make between these to be quantified [7].
The aim of this study was to evaluate osteoporotic pa-
tients’ preferences for medication attributes using a
DCE, and to establish how patients make trade-offs be-
tween these attributes. This study differs from previously
published DCEs in osteoporosis in several ways [8-10].
First, this study includes recently introduced routes andtral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Attributes and levels for osteoporosis drug
treatment
Efficacy in reducing the risk of future fractures 20%
30%
40%
50%
Possible side effects (affecting one in 50 patients) Gastrointestinal disorders
Flu-like symptoms
Skin reactions
Mode of administration Oral tablet
Subcutaneous injection
Intravenous injection
Frequency of administration Weekly
Monthly
Every 3 months
Every 6 months
Yearly
Cost to you (per month) €5
€15
€25
€40
€60
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intravenous injection) and the nature of potential side-
effects. Given potential differences in preferences be-
tween administration schemes, information on patients’
preferences for these new administration schemes would
be extremely useful for health professionals and
decision-makers [11]. Second, this study expands the
population studied to include men. Third, a rigorous
qualitative research was performed to select medication
attributes [12].
Methods
Discrete choice experiment
A DCE describes an intervention by its attributes (for
example, effectiveness, side-effects, costs) and reports
how patient’s preference for an intervention are influ-
enced by the type and levels of these attributes [7]. In
the DCE, patients were asked to choose between two
unlabelled drug treatments (A and B) and a no treat-
ment (opt-out) option. The alternative treatments varied
in several attributes, and patients were asked to select
the treatment they would prefer. Patients were asked to
make a series of such hypothetical choices. This research
followed published DCEs guidelines [1,13] and used
rigorous methods to select treatment attributes, to de-
sign the DCE and to conduct the statistical analysis.
Attributes and levels
The identification and selection of the DCE attributes is
fundamental to obtaining valid results [14,15]. We con-
ducted a nominal group technique to select the DCE at-
tributes [14]. Full details on this are provided elsewhere
[12]. In brief, patients’ group discussions (four to eight
participants per group, ntotal = 26) were conducted to
prioritize a list of potentially important attributes of
osteoporosis drug treatment. This list was developed
from a literature review and discussions with experts. A
ranking exercise and group discussions revealed five at-
tributes that were consistently identified as important
for patients: effectiveness, side-effects, mode and fre-
quency of administration and out-of-pocket cost
(Table 1) [12]. Levels were assigned to these attributes
based on the current treatment using a literature review
and discussion with experts (n = 5). For the side-effects
of treatment, we focused on the types of common side-
effects [16].
Experimental design
It is not feasible to present an individual with all possible
treatment combinations from the attributes and levels in
Table 1. Experimental design techniques were used to
draw a subset of treatment profiles to present to respon-
dents in the DCE [5]. Specifically, a Bayesian efficient
experimental design was used to select the subset usingNgene software (version 1.1.1) [17] to select the subset.
This experimental design maximizes the precision of es-
timated parameters (by maximizing the D efficiency – a
summary measure of the variance covariance matrix) for
a given number of choice questions [18]. In this study,
15 choice sets were created. An example of a choice set
is shown in Figure 1.
The construction of an efficient experimental design
depends on patients’ preferences, so we conducted a
pilot DCE study (n = 10). We used the pilot results to
obtain preliminary information about patients’ prefer-
ences and then used this information to create the ex-
perimental design for the main study. The pilot DCE
experimental design used a priori information about pa-
tients’ preferences based on literature review [9] and dis-
cussions during the qualitative research (for example,
higher effectiveness is preferred). We also wished to
avoid presenting respondents with implausible treatment
options (for example, a yearly oral tablet), and therefore
we restricted the experimental design to include only
realistic combinations between mode and frequency of
administration that could appear in the design (that is,
oral weekly or monthly tablets, subcutaneous injection
every 3 or 6 months, and intravenous injection every 3
months or yearly). The experimental design based
on pilot preference information suggested that 200
Figure 1 Example of a choice set.
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nificance of most parameters.
Questionnaire, data collection and patient recruitment
In the questionnaire, patients received a thorough de-
scription of the DCE task. The attributes and levels were
carefully explained and an example of a completed
choice set was provided. One of the choice questions
was asked twice to assess test–retest reliability. Each pa-
tient therefore received 16 choice sets. After completion
of the choice tasks, respondents were asked how difficult
they found the choice tasks on a seven-point scale. The
DCE task is presented in Additional file 1. The question-
naire also asked questions on patients’ characteristics.
Individual 10-year probabilities of a hip fracture and a
major osteoporotic fracture (FRAX score) [19] were cal-
culated for each respondent by a doctor/researcher and
added to the questionnaire afterwards.
The questionnaire was developed in English by a
working group that included a patient and clinical and
DCE experts, and was approved by two native English
speakers, experts in osteoporosis. The questionnaire was
then translated into French and Dutch by a medical
translation company specializing in the translation of pa-
tient reported outcome measures (Pharma Quest Ltd,
Oxford, United Kingdom) and the translation was
checked and approved by two native French and Dutch
speakers with medical backgrounds. The questionnaire
was pilot tested with 15 patients (French-speaking n =
10, Dutch-speaking n = 5) to check interpretation prob-
lems and face validity; no wording problems arose and
only minor changes to layout were made.
Consecutive patients with, or at risk of, osteoporosis
to whom medication (or lifestyle changes) was at least
proposed were recruited during outpatients’ clinics in
two Belgian osteoporosis centers (Ghent and Liège). Ex-
planation of the task and an example choice task was
provided by the doctor or a researcher. The question-
naire was mainly completed by the patient at home andreturned in a postage-paid envelope. Very few patients
completed the questionnaire at the clinic but without
any assistance from the doctor/researcher. Approval for
this study was obtained from the ethics committee of
Maastricht University Medical Center who coordinated
this project and participants gave informed written
consent.
Statistical analyses
From the DCE, we observe the respondent’s choice of
one treatment from the three alternatives presented in
each choice set. Responses are analyzed based on ran-
dom utility theory [20]. In this case, the utility that a pa-
tient i assigns to a treatment j,Vij, is modeled as the sum
of two parts: a systematic part based on the attributes
included in the DCE, and an error part εijt. We specify
Vij as:
V ij ¼ β0 þ β1 þ η1i
 
EFFICACYj þ β2 þ η2i
 
COSTj
þ β3 þ η3i
 
ORAL1Mj þ β4 þ η4i
 
SUB3Mj
þ β5 þ η5i
 
SUB6Mj þ β6 þ η6i
 
INT3Mj
þ β7 þ η7i
 
INT1Yj þ β8 þ η8i
 
FLUSYMPTj
þ β9 þ η9i
 
SKINREACTj þ εij
where β0 is the constant reflecting the preferences for
selecting treatment relative to no treatment, β1 to β9 are
the mean attribute utility weights in the population, and
η1i to η9i are error terms capturing individual-specific
unexplained variation in the utility weights. Dummy
coding was used (for ease of interpretation of the re-
sults) to describe all categorical variables (β3 to β9). Ref-
erence levels for mode of administration and for side
effects are weekly oral tablet and risk of gastrointestinal
disorders, respectively. The sign of the coefficient re-
flects whether the attribute/level has a positive or a
negative effect on treatment utility compared with the
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tive importance of the attribute/level.
When developing a statistical model of respondents’
choice it is important to account for respondents com-
pleting up to 15 choice tasks each and to allow prefer-
ences for treatment to vary across the sample. A mixed
logit panel data model was therefore estimated using
Nlogit, version 5 [21,22]. This model allows model pa-
rameters (preferences) to vary in the population. This
variation is achieved by specifying a random parameter
that has a distribution and estimating the mean (β) and
standard deviation of the error term (η) to capture the
parameter’s distribution. If the standard deviation is sig-
nificantly different from zero, this is interpreted as evi-
dence of significant preference variation for the attribute
in the sample.
Initially, we estimated models in which preferences for
all attributes could vary in the population, and then in the
final model – those attributes for which the estimated
standard deviation was not significant (5% level) – the
preferences were specified to be the same in the popula-
tion (fixed parameters). The random parameters for cost
and efficacy were drawn from a log-normal distribution –
this allows us to constrain the parameter estimate to be ei-
ther negative (for cost) or positive (for efficacy) [22]. All
other random parameters were drawn from a normal
distribution. The estimation was conducted using 2,000
Halton draws.
We also calculated marginal willingness to pay (WTP)
and marginal willingness to trade efficacy (WTTE) of
the attributes/levels. This allows us to compare prefer-
ences for all attributes measured with a common and in-
terpretable metric either money or efficacy. A WTP (or
WTTE) value represents how much one is willing to pay
(or to trade) for a one-unit change in the attribute, and
is calculating by taking the ratio of the mean parameter
for the attribute/level to the mean parameter related to
the cost (or efficacy). As the cost and efficacy variables
were estimated as random parameters, the WTP and
WTTE calculations must take this into account. As rec-
ommended in this case, the conditional constrained pa-
rameters were used [22].
The mixed logit model identifies attributes for which
there is significant preference variation, but it does not ex-
plain why this variation exists. To understand the potential
sources of preference variation, additional analyses in-
cluded covariates (such as gender, age) in the model one
by one. Significant covariates were then included together
and nonsignificant covariates were excluded from this
model. An adjusted pseudo-R2 and finite Akaike informa-
tion criterion were used to enable comparison of models
with and without covariates. We also tested whether
patients using a specific mode of administration had a
stronger preference for this administration scheme byincorporating interactions between levels and covariates.
Furthermore, to explore the impact of respondents who
failed the test–retest, a sensitivity analysis was conducted
by excluding these individuals. A subgroup analysis was
also conducted in patients with high risk of fractures
(defined as a FRAX major risk >10%) and in patients with
low risk of fractures (defined as a FRAX major risk ≤10%).
To assess the significance of the differences between popu-
lations, a joint model was estimated using interaction terms.
Results
Patients’ characteristics
A total of 301 questionnaires were distributed to patients;
268 were returned, representing a response rate of 89%.
Eleven questionnaires were excluded because the patient
did not complete at least five choice sets in the DCE task.
A total of 257 (85%) questionnaires were included for data
analysis. Respondents’ sociodemographics and health char-
acteristics are presented in Table 2. There was no restric-
tion on participation based on patients’ race and ethnicity
but patients were mainly Caucasian.
The difficulty of the task on a seven-point scale (1 =
extremely easy to 7 = extremely difficult) was estimated on
average between 3 and 4. The task was found to be ex-
tremely easy for 35 patients (13.6%) while 19 patients
(7.4%) gave a score of 6 of 7. A total of 219 patients
(85.2%) chose the same alternative in the test–retest exer-
cise. This is in line with existing test–retest results [15].
Patients’ preferences
The distribution of choices across the choice sets is pre-
sented in Additional file 2. The main results of the mixed
logit model are presented in Table 3. The estimated coeffi-
cients for efficacy and costs had the expected sign and
were statistically significant. The positive sign of the effi-
cacy parameter indicates that respondents prefer higher
treatment efficacy, and the negative sign of the cost par-
ameter indicates that respondents prefer paying less
money for treatment. Patients prefer a 6-month subcuta-
neous injection and a monthly oral tablet compared with a
weekly oral tablet (base level). There were no significant
differences between weekly oral tablet, 3-monthly sub-
cutaneous injection and yearly intravenous treatment; and
no significant differences between 6-monthly subcutane-
ous injection and monthly oral tablet. Regardless of the
administration mode, patients preferred a longer dosing
regimen (monthly vs. weekly oral tablet; 6-monthly vs. 3-
monthly subcutaneous injection; yearly vs. 3-monthly
intravenous treatment). The positive sign for the two side-
effect parameters indicates that patients disliked being at
risk of gastrointestinal disorders (base) more than being at
risk of skin reactions or flu-like symptoms.
The standard deviation parameters were statistically
significant for all attributes except for the subcutaneous
Table 2 Patients’ characteristics
Age (years, mean ± standard deviation) 67.1 ± 10.4
Female gender 83.3%
Educational level
Primary 8.4%
Some high school 35.9%
High school graduate 30.3%
College or university 25.5%
Size of household
One person 29.9%
Two people 55.1%
Three or more people 15.0%
Monthly household income
Up to €999 5.5%
€1,000 to 1,499 33.1%
€1,500 to 1,999 19.1%
€2,000 to 2,499 17.8%
€2,500 to 2,999 11.9%
€3,000+ 12.7%
Diagnosis of osteoporosis 89.8%
Years since osteoporosis (mean ± standard deviation) 8.9 ± 0.3
With prior fracture(s) 52.5%
In the last year 22.8%
Patients on osteoporotic treatment 69.8%
Administration mode of current treatment
Oral 72.2%
Subcutaneous injection 15.4%
Intravenous injection 12.4%
Number of co-treatments
Zero or one 19.3%
Two or three 40.6%
Four or more 40.2%
10-year probability of a major osteoporotic fracture (FRAX)
(mean ± standard deviation)
14.3 ± 7.5%
10-year probability of a hip fracture (FRAX)
(mean ± standard deviation)
6.1 ± 5.3%
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in the importance of the attribute/level across res-
pondents. To gain more insight into how preferences
vary, the distributions of the parameters or kernel dens-
ity estimates of the individual parameter are presented
in Additional file 3.
Willingness to pay
The WTP and WTTE for attributes/levels are presented
in Table 4. For example, respondents were willing to pay
a personal contribution of €19.53 more per month or togive up 13.52% of a drug’s efficacy for the treatment
mode of 6-month subcutaneous injection rather than a
weekly oral tablet.
High-risk patients versus low-risk patients
The results of the model for high-risk and low-risk pa-
tients are presented in Table 5. Significant differences in
preferences were found between these patient groups for
the effectiveness and cost of treatment – the interactions
between risk group and effectiveness and cost parame-
ters were significant (5% level)). Lower effectiveness and
higher costs are more acceptable for patients with high-
risk of fractures. In addition, high-risk patients attached
a higher (negative) value to being at risk for skin reac-
tions than low-risk patients, and the constant (that is,
preferences for drug treatment per se) was higher for
high-risk patients. Preferences for drug administration
did not differ significantly between patient groups.
Additional analyses
Excluding respondents who failed the test–retest (n =
38) had no impact on the relative importance of the at-
tributes (see Additional file 3). The inclusion of more
covariates into the model did not significantly improve
the adjusted McFadden’s pseudo-R2 but reduced the
sample size by 17% due to missing values (see Additional
file 3). We therefore did not include these covariates in
the reference model. The only significant covariate ef-
fects we observed were that the preference for drug
treatment was higher for men and patients with higher
income (monthly household income > €2,500 per
month). Other parameters were not affected by the in-
clusion of covariates. In addition, patients did not sig-
nificantly prefer their current mode of administration
over another mode of administration.
Discussion
This study suggests that patients with, or at risk of,
osteoporosis have preferences for medications’ attributes
and are willing to trade between attributes when making
treatment choices. Our results are consistent with a
priori expectations that patients prefer higher efficacy,
lower costs and less frequent dosing regimens. In
addition, patients preferred 6-month subcutaneous in-
jection or monthly oral tablet over weekly oral tablet or
intravenous injections, and they disliked being at risk for
gastrointestinal disorders. Patients are willing to trade
efficacy or to pay a personal contribution for better
levels of other attributes. For most of the attributes,
there was significant variation in patients’ preferences.
Previous DCEs have investigated women’s preference for
osteoporosis drug treatment [8-10]. Our results confirm
the findings of de Bekker-Grob and colleagues that patients
prefer monthly oral tablet to weekly oral tablet [9]
Table 3 Results from the panel mixed logit model
Attributes and levels Estimate (95% confidence interval) P value Standard deviation
Constant 0.90*** (0.62 to 1.17) 0.00 –
Efficacy (1% risk reduction) 0.07*** (0.05 to 0.08)a 0.00 1.19*** (1.06 to 1.30)
Cost per month (€1) −0.05*** (–0.04 to –0.06)a 0.00 1.24*** (1.09 to 1.39)
Drug administration (reference level: weekly oral tablet)
Monthly oral tablet 0.69*** (0.36 to 1.03) 0.00 0.92*** (0.65 to 1.19)
Subcutaneous injection 3-monthly 0.16 (–0.09 to 0.42) 0.21 NSb
Subcutaneous injection 6-monthly 0.75*** (0.44 to 1.07) 0.00 NS
Intravenous injection 3-monthly −0.57** (–1.12 to –0.01) 0.05 2.62*** (2.04 to 3.20)
Intravenous injection yearly 0.28 (–0.12 to 0.68) 0.17 1.56*** (1.17 to 1.94)
Side-effects (reference level: gastrointestinal disorders)
Flu-like symptoms 0.97*** (0.76 to 1.18) 0.00 0.90*** (0.65 to 1.15)
Skin reactions 0.63*** (0.41 to 0.85) 0.00 1.04*** (0.81 to 1.26)
Number of observations 3,822 (257 respondents × 15 choices, minus 33 missing values).
Pseudo-R2 = 0.42; log-likelihood = –2,456.03; Akaike information criterion = 1.29.
aFor the coefficients of efficacy and cost to you, exp(β) is shown. The standard deviation of the log-normal distribution is reported. bNot significant and not
included in the final model. **P < 0.05. ***P < 0.01.
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nificant difference in preference between weekly oral
regimen and yearly intravenous injection [8]. Fraenkel
and colleagues also showed that preferences are strongly
influenced by the route of administration but suggest a
majority (65%) of Americans preferred yearly intraven-
ous infusion over weekly oral tablet [10]. Our study ex-
pands on the insights of these studies. We expand the
population studied to include men, new recent adminis-
tration routes and frequencies (for example, 6-month
subcutaneous injection) and the nature of potential side-
effects. A rigorous qualitative research was also con-
ducted to select attributes.Table 4 Willingness to pay and willingness to trade efficacy f
Attributes and levels Willingn
(€ per
Efficacy (1% risk reduction) 3.73 (3.
Cost (€1)
Drug administration (reference level: weekly oral tablet)
Monthly oral tablet 16.16 (12
Subcutaneous injection 3-monthly 4.24 (3.
Subcutaneous injection 6-monthly 19.53 (17
Intravenous injection 3-monthly −15.28 (–2
Intravenous injection yearly 11.75 (5.
Side-effects (reference level: gastrointestinal disorders)
Flu-like symptoms 25.21 (13
Skin reactions 16.78 (13
Data presented as mean (95% confidence interval). A positive willingness to pay me
attribute/level, while a negative willingness to trade efficacy means that patients ar
conditional constrained distribution.Results of this study could be very useful for health pro-
fessionals and decision-makers, especially given the poor
adherence to weekly oral regimens and the potential dif-
ferences in healthcare costs associated with osteoporosis
medications. Nonadherence to medication is a major
problem among patients with osteoporosis and affects
considerably the effectiveness and cost-effectiveness of
drug therapy [23,24]. Determinants of poor adherence in-
clude inconvenient regimens [25]. In our study, many pa-
tients preferred a 6-monthly subcutaneous injection
compared with weekly oral tablets and yearly intravenous
injections. The recent introduction of 6-monthly subcuta-
neous injection of denosumab [26] and the recognition ofor osteoporosis medication attributesa
ess to pay Willingness to trade efficacy
month) (% risk reduction)
01 to 4.44) –
– −2.27 (–1.58 to –2.96)
.85 to 19.47) −10.16 (–7.88 to –12.50)
72 to 4.76) −2.93 (–2.57 to –3.30)
.15 to 21.92) −13.52 (–11.82 to –15.22)
3.23 to –7.34) 8.66 (14.31 to 3.01)
64 to 17.85) −5.83 (–1.88 to –9.77)
.06 to 20.50) −16.68 (–14.20 to –19.16)
.06 to 20.50) −9.48 (–7.13 to –11.83)
ans that patients are willing to pay a personal contribution for the
e willing to give up treatment efficacy for the attribute/level. aUsing the
Table 5 Differences between high-risk and low-risk patients’ preferences for osteoporosis drug treatment
Attributes and levels High risk patients Low-risk patients P valuea
(FRAX major >10%) (FRAX major ≤10%)
Number of patients 139 114
Pseudo-R2 0.39 0.42
Log-likelihood −1,378.35 −1,085.55
Constant 1.50*** (1.17 to 1.83) −0.05 (–0.52 to 0.43) 0.01
Efficacy (1% risk reduction) 0.04*** (0.03 to 0.04) 0.14*** (0.11 to 0.17) 0.00
SD: 1.65*** SD: 1.01***
Cost per month (€1) −0.02*** (–0.02 to –0.03) −0.08*** (–0.06 to –0.09) 0.00
SD: 1.45*** SD: 0.67***
Drug administration (reference level: weekly oral tablet)
Monthly oral tablet 0.57** (0.08 to 1.06) 1.14*** (0.47 to 1.82) 0.14
SD: 0.94*** SD: 1.87***
Subcutaneous injection 3-monthly 0.14 (–0.19 to 0.47) 0.28 (–0.17 to 0.74) 0.14
SD: NS SD: NS
Subcutaneous injection 6-monthly 0.57*** (0.17 to 0.96) 1.55*** (0.97 to 2.14) 0.06
SD: NS SD: NS
Intravenous injection 3-monthly −0.28 (–0.88 to 0.31) −0.24 (–1.39 to 0.91) 0.25
SD: 1.82*** SD: 4.84***
Intravenous injection yearly 0.28 (–0.13 to 0.69) 0.75** (0.05 to 1.45) 0.33
SD: 0.81*** SD: 2.15***
Side effects (reference level: gastrointestinal disorders)
Flu-like symptoms 0.66*** (0.36 to 0.95) 1.51*** (1.07 to 1.95) 0.57
SD: 0.91*** SD: 1.18***
Skin reactions 0.45** (0.05 to 0.85) 0.49** (0.10 to 0.87) 0.05
SD: 1.31*** SD: 1.04***
Data presented as estimate (95% confidence interval). SD, standard deviation; NS, not significant. aP value was estimated in a joint model with interaction terms.
**P < 0.05. ***P < 0.01.
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potentially improve patient satisfaction and adherence
with therapy [27]. Our results could also inform healthcare
decision-making, in particular for drug reimbursement,
where insights into the preferences of patients groups
should be taken into account alongside medical and eco-
nomic considerations [28].
In addition, the variation in the patients’ preferences
for attribute levels observed in our study highlights the
importance to take into account individual preferences
into clinical decision-making to improve osteoporosis
care. Relying solely on sample average preferences will
probably be insufficient to optimize medical doctors’
sensitivity to the preferences of an individual and unique
patient during a consultation. Informing individual pa-
tients about alternative options and their outcomes, and
involving them in decision-making, would be very im-
portant to improve patient satisfaction and the outcome
of medical care [29].Our study has some potential limitations. First, al-
though consecutive patients were invited to participate
in this study, we cannot exclude selection bias as some
patients did not want, or were not able, to fill in the
questionnaire. Second, generalizability and transferability
of our findings may be limited by recruiting patients
from two osteoporosis centers in one country only. A
cross-country comparison is ongoing in seven European
countries. Preferences for attributes/levels may differ ac-
cording to a number of factors including age, income,
education or prior fractures [30]. While we do not find
evidence of preference variation associated with these
factors in our study, the cross-country comparison will
investigate this further. Third, we focused on the nature
of common side-effects, not on their frequency and rare
complications. Rare adverse events will be as (in)fre-
quent in all categories of anti-resorptive drugs. There-
fore, adding osteonecrosis of the jaw and atypical
femoral fracture to the side-effect attribute would
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across existing drugs. Attributes were selected using a
rigorous qualitative method as recommended in good
practice guidelines [1,13]. Finally, one could point out
that the individual 10-year probability of fractures was
not provided to the patients before completing the ques-
tionnaire. Only 35 (14%) patients reported knowing their
FRAX score.
Conclusions
This study revealed that osteoporotic patients prefer 6-
monthly subcutaneous injection and oral monthly tab-
lets, and disliked gastrointestinal disorders. Moreover,
they were willing to trade efficacy or to pay a personal
contribution for their preferred outcomes. We found dif-
ferences in preferences across patients, which highlights
the importance of clinical decision-making taking indi-
vidual preferences into account to improve osteoporosis
care.
Additional files
Additional file 1: The questionnaire given to the patients.
Additional file 2: A table presenting the distribution of choices
(treatment A, treatment B, no treatment) across the 15 choice sets.
Additional file 3: Shows tables and figures presenting additional
results including estimates of models with excluding respondents
who failed the test–retest or with inclusion of covariates, and
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